Swanson Health Sale Could Lead Private Equity Spike In Supplement Space
This article was originally published in The Tan Sheet
Executive Summary
Swander Pace Capital's Swanson Health deal announced Jan. 25 is the firm's second in two months in the supplement industry after acquiring Captek Softgel in December. OTC drug and supplement firms in 2016 could be among the consumer product spaces targeted in likely higher private equity investing.
You may also be interested in...
Consumer Health Sector Holds Private Equity Investors' Attention
"It's amazing with this consumer empowerment how fast that market is growing," biopharma industry veteran Fred Hassan remarks. "Coming up with good products, scientifically validated, supported by doctors and approaching consumers with proper claims, it's a huge opportunity."
Consumer Health Sector Holds Private Equity Investors' Attention
"It's amazing with this consumer empowerment how fast that market is growing," biopharma industry veteran Fred Hassan remarks. "Coming up with good products, scientifically validated, supported by doctors and approaching consumers with proper claims, it's a huge opportunity."